Aladin Mawani - Extendicare Independent Director
| EXE Stock | CAD 10.54 0.21 2.03% |
Director
Mr. Aladin W. Mawani is Independent Director of the Company. Mr. Mawani is the Principal of Exponent Capital Partners Inc., a private equity investor and real estate advisory firm. He has over 35 years of experience in the commercial real estate industry, including 15 years of csuite experience as SVPEVP CFO of Oxford Properties Group Inc. from 1989 to 2001, President and CEO of CallowaySmart Centres Real Estate Investment Trust from 2011 to 2013, and President CEO of privatelyowned Rodenbury Investments Limited during 2015 and 2016. Mr. Mawani was an independent board member of national and North American firms across multiple asset classes, including privatepay retirement living operations. He currently serves on the TSXlisted boards of First Capital Realty Inc., as Chair of its Audit Committee, and Granite REIT, as Chair of its Corporationrationrate Governance Nominating Committee and as a member of its Audit Committee, and is a member of the advisory board of Elevate Multifamily LP, a private real estate investment fund. In addition, he has served on the boards of Slate Office REIT, Boardwalk Real Estate Investment Trust, Calloway Real Estate Investment Trust, Amica Mature Lifestyles Inc., and IPC US Real Estate Investment Trust since 2017.
| Age | 67 |
| Tenure | 7 years |
| Professional Marks | CPA |
| Address | 3000 Steeles Avenue East, Markham, ON, Canada, L3R 4T9 |
| Phone | 905 470 4000 |
| Web | https://www.extendicare.com |
Extendicare Management Efficiency
The company has return on total asset (ROA) of 0.0716 % which means that it generated a profit of $0.0716 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.6 %, meaning that it generated $0.6 on every $100 dollars invested by stockholders. Extendicare's management efficiency ratios could be used to measure how well Extendicare manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Extendicare's Return On Tangible Assets are very stable compared to the past year. As of the 27th of November 2024, Return On Capital Employed is likely to grow to 0.26, while Return On Equity is likely to drop 0.30. At this time, Extendicare's Fixed Asset Turnover is very stable compared to the past year. As of the 27th of November 2024, Return On Assets is likely to grow to 0.05, while Non Currrent Assets Other are likely to drop about 33.2 M.Management Performance
| Return On Equity | 0.6 | ||||
| Return On Asset | 0.0716 |
Extendicare Leadership Team
Elected by the shareholders, the Extendicare's board of directors comprises two types of representatives: Extendicare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Extendicare. The board's role is to monitor Extendicare's management team and ensure that shareholders' interests are well served. Extendicare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Extendicare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ali Mir, Vice President - ParaMed Operations | ||
| Samir Manji, Independent Director | ||
| Brent Houlden, Independent Director | ||
| Kathryn Bradley, Vice Development | ||
| MBA MD, President CEO | ||
| Amie Vahrmeyer, Vice ON | ||
| Jillian Fountain, Vice President - Investor Relations | ||
| Liselie Sarauer, Chief Human Resource Officer, Senior Vice President | ||
| Katie LeMoyne, Senior Officer | ||
| Bruce Wienberg, VP Care | ||
| Elaine Everson, Vice President - Corporate Development | ||
| Danielle Parr, Vice Affairs | ||
| Sandra Hanington, Independent Director | ||
| Wendy Gilmour, Senior Operations | ||
| Lisa Pearson, VP Affairs | ||
| Alan Hibben, Independent Director | ||
| David Bacon, Chief Financial Officer, Senior Vice President | ||
| Matthew Morgan, Chief Officer | ||
| Leslie Sarauer, VP Officer | ||
| Donna Kingelin, Independent Director | ||
| Joe Belinsky, VP Officer | ||
| Alan Torrie, Independent Chairman of the Board | ||
| Michael Guerriere, President, Chief Executive Officer, Director | ||
| Norma Beauchamp, Independent Director | ||
| John Toffoletto, Senior Vice President Chief Legal Officer and Corporate Secretary | ||
| Steve Paraskevopoulos, Senior CTO | ||
| Aladin Mawani, Independent Director |
Extendicare Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Extendicare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.6 | ||||
| Return On Asset | 0.0716 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 1.03 B | ||||
| Shares Outstanding | 83.47 M | ||||
| Shares Owned By Insiders | 13.92 % | ||||
| Shares Owned By Institutions | 19.14 % | ||||
| Number Of Shares Shorted | 848.63 K | ||||
| Price To Earning | 26.74 X |
Pair Trading with Extendicare
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Extendicare position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Extendicare will appreciate offsetting losses from the drop in the long position's value.Moving together with Extendicare Stock
Moving against Extendicare Stock
The ability to find closely correlated positions to Extendicare could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Extendicare when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Extendicare - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Extendicare to buy it.
The correlation of Extendicare is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Extendicare moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Extendicare moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Extendicare can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Extendicare Stock
Extendicare financial ratios help investors to determine whether Extendicare Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Extendicare with respect to the benefits of owning Extendicare security.